Midatech Pharma
Market Cap
UK£17.2m
Last Updated
2019/11/10 21:36 UTC
Data Sources
Company Financials +
Executive Summary
Midatech Pharma plc, a biotechnology company, focuses on the research and development of oncology and rare disease products in the United Kingdom.
Snowflake
Fundamentals
Adequate balance sheet with questionable track record.
Similar Companies
Share Price & News
How has Midatech Pharma's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MTPH's share price has been volatile over the past 3 months.
Market Performance
7 Day Return
-9.9%
MTPH
3.0%
GB Biotechs
0.5%
GB Market
1 Year Return
-72.5%
MTPH
0.5%
GB Biotechs
2.8%
GB Market
Return vs Industry: MTPH underperformed the UK Biotechs industry which returned 0.5% over the past year.
Return vs Market: MTPH underperformed the UK Market which returned 2.8% over the past year.
Shareholder returns
| MTPH | Industry | Market | |
|---|---|---|---|
| 7 Day | -9.9% | 3.0% | 0.5% |
| 30 Day | -39.2% | 7.4% | 1.7% |
| 90 Day | -36.0% | 4.7% | 3.7% |
| 1 Year | -72.5%-72.5% | 1.4%0.5% | 8.2%2.8% |
| 3 Year | -96.9%-96.9% | 4.3%2.3% | 24.3%8.5% |
| 5 Year | n/a | 44.0%40.3% | 35.1%4.3% |
Price Volatility Vs. Market
How volatile is Midatech Pharma's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
Do Institutions Own Shares In Midatech Pharma Plc (LON:MTPH)?1 year ago | Simply Wall St
How Does Midatech Pharma Plc (LON:MTPH)’s Prospect Stack Up To Its Healthcare Peers?1 year ago | Simply Wall St
Does Midatech Pharma Plc's (LON:MTPH) Recent Track Record Look Strong?Valuation
Is Midatech Pharma undervalued compared to its fair value and its price relative to the market?
0.6x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate MTPH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate MTPH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: MTPH is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: MTPH is unprofitable, so we can't compare its PE Ratio to the UK market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MTPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MTPH is good value based on its PB Ratio (0.6x) compared to the GB Biotechs industry average (2.1x).
Next Steps
Future Growth
How is Midatech Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
-16.7%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MTPH is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: MTPH is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: MTPH is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: MTPH's revenue (84.8% per year) is forecast to grow faster than the UK market (3.8% per year).
High Growth Revenue: MTPH's revenue (84.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if MTPH's Return on Equity is forecast to be high in 3 years time
Next Steps
Past Performance
How has Midatech Pharma performed over the past 5 years?
-4.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MTPH has high quality earnings.
Growing Profit Margin: MTPH's current net profit margins (-497.9%) are higher than last year (-1060%).
Past Earnings Growth Analysis
Earnings Trend: MTPH is unprofitable, and losses have increased over the past 5 years at a rate of -4% per year.
Accelerating Growth: Unable to compare MTPH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MTPH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (5.4%).
Return on Equity
High ROE: MTPH has a negative Return on Equity (-37.04%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Next Steps
Financial Health
How is Midatech Pharma's financial position?
Financial Position Analysis
Short Term Liabilities: MTPH's short term assets (£14.3M) exceeds its short term liabilities (£3.4M)
Long Term Liabilities: MTPH's short term assets (14.3M) exceeds its long term liabilities (383.0K)
Debt to Equity History and Analysis
Debt Level: MTPH's debt to equity ratio (3.4%) is considered satisfactory
Reducing Debt: MTPH had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Inventory Level: MTPH has a low level of unsold assets or inventory.
Debt Coverage by Assets: MTPH's debt is covered by short term assets (assets are 17x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MTPH has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: MTPH has less than a year of cash runway if free cash flow continues to grow at historical rates of 12.3% each year.
Next Steps
Dividend
What is Midatech Pharma's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate MTPH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MTPH's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MTPH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MTPH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MTPH's dividend in 3 years as they are not forecast to pay a notable one for the UK market.
Next Steps
Management
What is the CEO of Midatech Pharma's salary, the management and board of directors tenure and is there insider trading?
1.5yrs
Average management tenure
CEO
Craig Cook (52yo)
1.4yrs
Tenure
UK£158,772
Compensation
Dr. Craig Richard Cook, MBBCH, BSc (Hons), DA, MD, MBA has been Chief Executive Officer and Director of Midatech Pharma Plc since June 1, 2018 and served as its Chief Operating Officer since January 1, 201 ...
CEO Compensation Analysis
Compensation vs Market: Craig's total compensation ($USD203.02K) is below average for companies of similar size in the UK market ($USD319.03K).
Compensation vs Earnings: Insufficient data to compare Craig's compensation with company performance.
Management Age and Tenure
1.5yrs
Average Tenure
54yo
Average Age
Experienced Management: MTPH's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Age and Tenure
4.9yrs
Average Tenure
58.5yo
Average Age
Experienced Board: MTPH's board of directors are considered experienced (4.9 years average tenure).
Insider Trading
Insider Buying: MTPH insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
| Entity | Individual |
| Role | Member of the Board of Directors CFO & Director |
| Shares | 250,000 |
| Max Price | UK£0.055 |
| Entity | Individual |
| Role | Member of the Board of Directors CFO & Director |
| Shares | 200,000 |
| Max Price | UK£0.053 |
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 215.5%.
Management Team
Stephen Stamp (57yo)
CFO & Director
- Tenure: 0.2yrs
Tim Sparey
Chief Business Officer
- Tenure: 0yrs
Craig Cook (52yo)
CEO & Director
- Tenure: 1.4yrs
- Compensation: UK£158.77k
Justin Barry
Head of Manufacturing
- Tenure: 0yrs
David Benharris (54yo)
President of Midatech Pharma US Inc
- Tenure: 3.8yrs
Steve Damment
Head of Research & Development
- Tenure: 1.7yrs
Board Members
Simon Turton (51yo)
Senior Independent Non-Executive Director
- Tenure: 4.9yrs
- Compensation: UK£30.40k
Rolf Stahel (75yo)
Non-Executive Chairman
- Tenure: 5.7yrs
- Compensation: UK£95.00k
Stephen Stamp (57yo)
CFO & Director
- Tenure: 0.2yrs
Dan McCurdy (62yo)
Member of Scientific Advisory Board
- Tenure: 0yrs
Simon de Vries (60yo)
Non-Executive Director
- Tenure: 15.1yrs
- Compensation: UK£30.40k
Craig Cook (52yo)
CEO & Director
- Tenure: 1.4yrs
- Compensation: UK£158.77k
Francesco Stellaci
Chairman of Scientific Advisory Board
- Tenure: 0yrs
David Male
Member of Scientific Advisory Board
- Tenure: 0yrs
Lorraine O'Driscoll
Member of Scientific Advisory Board
- Tenure: 0yrs
Soledad Penades
Member of Scientific Advisory Board
- Tenure: 0yrs
Company Information
Midatech Pharma plc's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Midatech Pharma plc
- Ticker: MTPH
- Exchange: AIM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: UK£17.151m
- Shares outstanding: 469.90m
- Website: https://www.midatechpharma.com
Number of Employees
Location
- Midatech Pharma plc
- Oddfellows House
- 19 Newport Road
- Cardiff
- South Glamorgan
- CF24 0AA
- United Kingdom
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| MTPH | AIM (London Stock Exchange AIM Market) | Yes | Ordinary Shares | GB | GBP | Dec 2014 |
| 5MPB | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Dec 2014 |
| MTP | NasdaqCM (Nasdaq Capital Market) | SPON ADS EACH REP 20 ORD SHS(R/S) | US | USD | Dec 2015 | |
| 5MPC | BST (Boerse-Stuttgart) | SPON ADS EACH REP 20 ORD SHS(R/S) | DE | EUR | Dec 2015 |
Biography
Midatech Pharma plc, a biotechnology company, focuses on the research and development of oncology and rare disease products in the United Kingdom. The company is developing MTD201, a long acting dose of Oc ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2019/11/10 21:36 |
| End of Day Share Price | 2019/11/08 00:00 |
| Earnings | 2019/06/30 |
| Annual Earnings | 2018/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.